Amgen and AstraZeneca's TEZSPIRE Shows Promise in Phase 3 Trial of Eosinophilic Esophagitis

AstraZeneca and Amgen announced positive results from the Phase 3 CROSSING trial of TEZSPIRE in patients living with eosinophilic esophagitis (EoE). The study demonstrated that TEZSPIRE showed statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24, which were sustained through week 52.

TEZSPIRE is a first-in-class human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that initiates an overreactive immune response to allergic and other types of epithelial-driven inflammation. The treatment is currently approved for severe asthma in the U.S., EU, China, Japan, and more than 70 countries globally.

'We're pleased that TEZSPIRE showed efficacy in a third epithelial-driven inflammatory condition, eosinophilic esophagitis,' said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. 'In this Phase 3 trial, TEZSPIRE improved both the underlying inflammation and the swallowing difficulties that can make eosinophilic esophagitis so disruptive for patients.'

EoE is a chronic and progressive epithelial-driven inflammatory disorder of the esophagus affecting more than 470,000 people in the U.S., with the prevalence increasing five-fold since 2009. The study highlighted the need for new treatments as nearly half of patients do not achieve adequate disease control with current first-line therapies.